（文章来源：每日经济新闻） 2024年1至12月份，ST葫芦娃的营业收入构成为：医药制造业占比100.0%。 ST葫芦娃（SH 605199，收盘价：9.23元）8月4日晚间发布公告称，公司第三届2025年第四次董事会临 时会议于2025年8月4日在海南省海口市秀英区安读一路30号公司会议室以现场结合通讯方式召开。会议 审议了《关于补选第三届董事会董事候选人的议案》等文件。 ...

Group 1 - The company Zhejiang Zhenyuan announced the appointment of Zhou Qiaomi as the new general manager and Zhang Bin as the new financial director, with Zhang Yufeng stepping down from the financial director role [2] - For the fiscal year 2024, the revenue composition of Zhejiang Zhenyuan is projected to be 82.04% from commercial activities and 17.96% from industrial-pharmaceutical manufacturing [2]

（文章来源：每日经济新闻） 浙江震元（SZ 000705，收盘价：9.57元）8月4日晚间发布公告称，公司第十一届2025年第三次董事会 临时会议于2025年8月4日以通讯形式召开。会议审议了《关于增补第十一届董事会董事的议案》等文 件。 2024年1至12月份，浙江震元的营业收入构成为：商业占比82.04%，工业-医药制造占比17.96%。 ...

博弈调令 ? 8月4日A股市场投资情绪 资本市场是投资者信心的晴雨表。投资者情绪的波动会影响其对未 的主观判断,进而影响投资行为,形成合力后对市场产生显著影响 想通过几个问题，了解投资者对每日市场的看法。8月4日共有8740 户参与了调研，具体情况如下： 上证指数 创 业 板 深证成指 ▲ 0.66% ▲ 0.46% ▲ 0.50 A股低开高走，三大股指小幅上涨，均完成日内V型反转，技术面上，沪指2 支撑有效，MACD红柱缩短但未形成死叉，短期需关注3600点压力位。 3875家上涨 涨跌停比 个股涨多跌少,全市场超 3800 只个股上涨,赚 钱效应极好,中小盘股表现活跃,军工板块全线 走强,医药、人形机器人概念午后拉升,贵金属、 液冷服务器等板块涨幅居前,创新药板块多股跌 停。 两市成交额 7元▼6.269 131 s 亚 15 - 主力资金净流出 3.5 亿元 散户资金净流入 机构呈"防御性调仓与政策博弈" 特征，资金从高估值赛道流向军工、贵金属等防御板块，同时布局机 等政策催化方向；散户呈"亢奋与分化并存"特征，集中参与军工、机器人等热点题材，杠杆资金加仓 但风险偏好过高，跟风行为明显，资金分散目缺乏持 ...

Group 1 - The company, Jianyou Co., Ltd. (SH 603707), announced on August 4 that it has repurchased a total of 880,000 shares through the Shanghai Stock Exchange, accounting for 0.05% of its total share capital [2] - The repurchase was conducted at a minimum price of 11.58 CNY per share and a maximum price of 11.66 CNY per share, with a total expenditure of 10.22 million CNY [2] - For the year 2024, the company's revenue composition indicates that 99.85% comes from the pharmaceutical manufacturing industry, while other businesses contribute 0.15% [2]

Core Viewpoint - The article discusses the current state of the stock market, highlighting that while the Shanghai and Shenzhen indices have reached 3600 points, many stocks have seen significant declines, indicating a potential re-evaluation of value in the consumer sector and other industries [2][4]. Group 1: Consumer Sector Challenges - The consumer sector is experiencing a downturn, with notable declines in stocks such as Qiaqia Food (-15.91%) and Fuling Pickles (-4.21%), reflecting a broader trend of value reassessment in national brands amidst the new consumption era [7]. - The transition in the soy sauce industry from "volume growth" to "price growth" is causing short-term profit pressures as companies invest in high-end products, similar to Japan's Kikkoman's long-term transformation [7]. Group 2: Innovation and Market Dynamics - The pharmaceutical and medical device sectors are facing harsh realities, with price reductions in generic drugs and medical devices forcing companies to reassess their R&D investments [9]. - The divergence between the performance of the CSI 300 index (+3.05%) and individual stocks illustrates the market's short-term voting behavior versus long-term valuation [9]. - Companies with stable cash flow, clear competitive landscapes, and untapped growth potential are seen as value opportunities in the current market [9]. Group 3: Investment Opportunities - Low stock performance is viewed as a starting point for re-evaluating value, prompting questions about the sustainability of business models, management's value creation for shareholders, and whether current valuations reflect pessimistic expectations [10]. - The article emphasizes that true investment opportunities often lie in market sentiment lows, where companies like Jin Zai Food and Jingxin Pharmaceutical may show signs of improvement [10]. - The stock market is characterized by dynamic boundaries between low performance and high growth, necessitating a long-term perspective to navigate short-term fluctuations [10].

金融界消息 截至2025年8月4日收盘，博瑞医药（688166）报收于98.07元，下跌1.19%，换手率3.47%， 成交量14.68万手，成交金额14.49亿元。 资金流向方面，今日主力资金净流入5678.69万元，占比成交额3.92%。其中，超大单净流出2136.60万 元、占成交额1.47%，大单净流入7815.29万元、占成交额5.39%，中单净流出流出1195.96万元、占成交 额0.83%，小单净流出4482.72万元、占成交额3.09%。 天眼查商业履历信息显示，博瑞生物医药(苏州)股份有限公司，成立于2001年，位于苏州市，是一家以 从事医药制造业为主的企业。企业注册资本42246.505万人民币，实缴资本22062.4827万人民币。公司法 定代表人为袁建栋。 通过天眼查大数据分析，博瑞生物医药(苏州)股份有限公司共对外投资了38家企业，参与招投标项目49 次，知识产权方面有商标信息121条，专利信息178条，此外企业还拥有行政许可37个。 来源：金融界 博瑞医药最新一期业绩显示，截至2025一季报，公司营业总收入2.49亿元、同比减少26.81%，归属净利 润1295.98万元，同比减少 ...

Global Core Risks - Geopolitical conflicts, such as the Russia-Ukraine war and tensions in the Middle East, are significant risks affecting global markets, leading to increased oil and gold prices and higher supply chain costs [2][4] - The Federal Reserve's policies and the dollar cycle have profound impacts on global financial markets; prolonged high interest rates could suppress valuations of A-share growth stocks, while fluctuations in the dollar affect foreign capital inflows [2][4] - The strength of China's economic recovery is crucial for the A-share market, with weak real estate and consumption potentially pressuring cyclical stocks, while emerging industries like renewable energy and AI may present structural opportunities [4] Safe Asset Allocation - Gold is highlighted as a key safe-haven asset, with investors encouraged to consider gold ETFs for liquidity and gold stocks for potential upside, particularly during geopolitical crises or currency devaluation [5] - High-dividend assets serve as a defensive tool against market volatility, with banks and utilities providing stable cash flows and low valuations, making them suitable for conservative investors [6] - Government bonds and interest rate bonds are considered low-risk havens, with options for short-term liquidity management through reverse repos and long-term holdings via bond ETFs [7] - Essential consumer goods and pharmaceuticals are identified as defensive sectors with strong demand characteristics, benefiting from brand loyalty and demographic trends [8] A-share Adaptation Strategies - A core-satellite strategy is recommended for portfolio construction, with a core allocation of 60% in high-dividend assets, gold ETFs, and government bonds for stability, while 40% can be flexibly allocated based on market conditions [9] - Investors should focus on policy-driven industry rotations, with potential benefits for sectors like machinery and consumer goods from government incentives, while avoiding high-debt real estate and export-dependent sectors [10] - Dynamic rebalancing of the investment portfolio is advised, adjusting allocations based on market movements, such as increasing high-dividend assets during market downturns [11] Summary and Practical Recommendations - In the context of global risks, geopolitical conflicts and Federal Reserve policies are critical external variables that require ongoing monitoring [12] - A suggested asset allocation includes 20% in gold, 30% in high-dividend assets, and 10% in government bonds to create a safety net against market risks [12] - Conservative investors are encouraged to focus on sectors like electricity, coal, and utilities, while aggressive investors may consider technology and resource sectors during market corrections [12] - Flexibility in response to market changes is essential, with adjustments based on Federal Reserve actions and inflation trends to optimize asset allocation [12][13]

Group 1: Macro Economic Insights - The US non-farm payrolls for July showed a significant drop, with only 73,000 jobs added, far below the expected 110,000, and previous months' data was revised downwards by 258,000 jobs [2][3] - The unemployment rate rose to 4.25%, while hourly wages increased year-on-year to 3.91%, indicating a mixed labor market scenario [2][3] - Market expectations for interest rate cuts have increased, with traders anticipating three cuts totaling 75 basis points by December 2025, reflecting concerns over economic weakness [6][8] Group 2: Chemical Industry Insights - The polyester filament industry is experiencing a concentration of production capacity, with leading companies increasing their market share, resulting in a more orderly supply environment [19][22] - Demand for polyester filament remains stable, with a seasonal uptick expected in the second half of the year as inventory levels are low [20][22] - The cost pressures from raw materials are expected to ease, with oil price fluctuations influencing the cost structure of polyester filament production [21][22] Group 3: Pharmaceutical Industry Insights - The pharmaceutical sector is witnessing a recovery in public fund holdings, with a notable increase in the market value of heavy holdings, indicating a structural rebound [25][28] - Recent policy changes in drug procurement are expected to favor quality over price, potentially stabilizing profit margins for innovative drug and device companies [26][28] - The medical device market is showing signs of recovery, with significant growth in tendering activities, particularly in medical imaging and rehabilitation equipment [27][28] Group 4: North Exchange Market Insights - The North Exchange market has seen a decline in trading activity, with the average daily turnover dropping to approximately 251 billion yuan [31][32] - The overall market valuation remains high, with the North Exchange's price-to-earnings ratio at around 50.9 times, indicating potential for long-term investment value [32][34] - The introduction of new indices and steady progress in IPOs are expected to maintain a high level of market interest and activity [34]

Group 1 - The core viewpoint of the news is that Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd. has shown a slight increase in revenue but a decrease in net profit in its latest quarterly report [1] - As of August 1, 2025, the company's stock price closed at 14.31 yuan, down 2.32%, with a trading volume of 239,600 hands and a transaction amount of 353 million yuan [1] - The company's main funds experienced a net outflow of 13.46 million yuan, accounting for 3.82% of the transaction amount, with significant outflows from large orders [1] Group 2 - For the first quarter of 2025, the company reported total operating revenue of 248 million yuan, a year-on-year increase of 4.28%, while the net profit attributable to shareholders decreased by 5.30% to 47.18 million yuan [1] - The company has a current ratio of 4.936, a quick ratio of 4.556, and a debt-to-asset ratio of 35.72% [1] - Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd. was established in 2001 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of approximately 2.34 billion yuan [1][2]